Summary
Regional connectivity and land-based travel have been identified as important drivers of SARS-CoV-2 transmission. However, the generalizability of this finding is understudied outside of well-sampled, highly connected regions such as Europe. In this study, we investigated the relative contributions of regional and intercontinental connectivity to the source-sink dynamics of SARS-CoV-2 for Jordan and the wider Middle East. By integrating genomic, epidemiological and travel data we show that the source of introductions into Jordan was dynamic across 2020, shifting from intercontinental seeding from Europe in the early pandemic to more regional seeding for the period travel restrictions were in place. We show that land-based travel, particularly freight transport, drove introduction risk during the period of travel restrictions. Consistently, high regional connectivity and land-based travel also disproportionately drove Jordan’s export risk to other Middle Eastern countries. Our findings emphasize regional connectedness and land-based travel as drivers of viral transmission in the Middle East. This demonstrates that strategies aiming to stop or slow the spread of viral introductions (including new variants) with travel restrictions need to prioritize risk from land-based travel alongside intercontinental air travel to be effective.
Highlights
Regional connectivity drove SARS-CoV-2 introduction risk in Jordan during the period travel restrictions were in place in genomic and travel data.
Land-based travel rather than air travel disproportionately drove introduction risk during travel restrictions.
High regional connectivity disproportionately drove Jordan’s export risk, with significant contribution from land-based travel.
Regional transmission dynamics were underestimated in genomic data due to unrepresentative sampling.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been funded by CDC BAA contracts 75D30120C09795 (K.G.A.), NIH NIAID 3U19AI135995-03S2 (K.G.A.), U19AI135995 (K.G.A.), U01AI151812 (K.G.A.), NIH NCATS UL1TR002550 (K.G.A.), NIH NIAID R01 AI135992 (J.O.W). This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Numbers 1U01AI151378-01 (subaward Number 8-312-0217530-66439L). Experimental part conducted by Marceline Cote's laboratory was supported by a COVID-19 Rapid Research grant from the Canadian Institutes for Health Research (OV3 170632) to M.C. M.C. is a Canada Research Chair in Molecular Virology and Antiviral Therapeutics and a recipient of an Ontario Early Researcher Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Boards (IRBs) at Scripps Research Institute (TSRI) (IRB-21-7739) and the Cell Therapy Center of The University of Jordan (IRD-CTC/1- 2020/01)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced are available online at https://github.com/andersen-lab/paper_2022_jordan-sars2-phylogenetics.
https://github.com/andersen-lab/paper_2022_jordan-sars2-phylogenetics.
